TrialAnnals of oncology : official journal of the European Society for Medical Oncology2015

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.

G R Blumenschein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.